Abstract
The nuclear factor κB (NF-κB) plays an important role in tumorigenesis by affecting processes such as tumor initiation, promotion, growth, and metastasis. NF-κB induces the expression of genes that are known to confer resistance to apoptosis. Therefore, its activation has been associated with the development of chemo- and radiation resistance in cancer cells. NF-κB is constitutively activated in many types of tumor cells by mechanisms that are not well understood. Like NF-κB, tissue-type transglutaminase (TG2), the most diverse and ubiquitous member of the calcium-dependent transglutaminase family of enzymes, is also aberrantly overexpressed in many human cancer types, blocks apoptosis, and promotes drug resistance and metastatic phenotypes. In this review, we will discuss the current understanding of the mechanisms thought to participate in constitutive activation of NF-κB. Particular focus is given to the implications of increased TG2 expression in NF-κB activation and its contributions to the development of drug resistance and metastatic phenotypes in cancer cells.
Keywords: IKK-Independent Pathways, Apoptosis, extracellular matrix, phosphorylation, metastasis
Current Cancer Drug Targets
Title: Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Volume: 7 Issue: 6
Author(s): Amit Verma and Kapil Mehta
Affiliation:
Keywords: IKK-Independent Pathways, Apoptosis, extracellular matrix, phosphorylation, metastasis
Abstract: The nuclear factor κB (NF-κB) plays an important role in tumorigenesis by affecting processes such as tumor initiation, promotion, growth, and metastasis. NF-κB induces the expression of genes that are known to confer resistance to apoptosis. Therefore, its activation has been associated with the development of chemo- and radiation resistance in cancer cells. NF-κB is constitutively activated in many types of tumor cells by mechanisms that are not well understood. Like NF-κB, tissue-type transglutaminase (TG2), the most diverse and ubiquitous member of the calcium-dependent transglutaminase family of enzymes, is also aberrantly overexpressed in many human cancer types, blocks apoptosis, and promotes drug resistance and metastatic phenotypes. In this review, we will discuss the current understanding of the mechanisms thought to participate in constitutive activation of NF-κB. Particular focus is given to the implications of increased TG2 expression in NF-κB activation and its contributions to the development of drug resistance and metastatic phenotypes in cancer cells.
Export Options
About this article
Cite this article as:
Verma Amit and Mehta Kapil, Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity, Current Cancer Drug Targets 2007; 7 (6) . https://dx.doi.org/10.2174/156800907781662275
DOI https://dx.doi.org/10.2174/156800907781662275 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Approaching Inherited Disease on a Genomic Scale
Current Genomics Transcription Factors as Molecular Targets: Molecular Mechanisms of Decoy ODN and their Design
Current Drug Targets microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Recent Progress in the Pharmacology of Imidazo[1,2-a]pyridines
Mini-Reviews in Medicinal Chemistry Mechanisms Underlying Chemopreventive Effects of Flavonoids via Multiple Signaling Nodes within Nrf2-ARE and AhR-XRE Gene Regulatory Networks
Current Chemical Biology Could Growth Factor-Mediated Extracellular Matrix Deposition and Degradation Offer the Ground for Directed Pharmacological Targeting in Fibrosarcoma?
Current Medicinal Chemistry Cell Penetrating Peptides as a Therapeutic Strategy in Chronic Lymphocytic Leukemia
Protein & Peptide Letters Recent Advancements for the Management of Pancreatic Cancer: Current Insights
Current Cancer Therapy Reviews Screening Neuroprotective Agents Through 4-hydroxynonenal, Ethanol, High Glucose, Homocysteine, Okadaic Acid, Rotenone, and Oxygen-Glucose Deprivation Induced PC12 Injury Models: A Review
Current Psychopharmacology CXCR7 Participates in CXCL12-mediated Cell Cycle and Proliferation Regulation in Mouse Neural Progenitor Cells
Current Molecular Medicine Instructions from the Vascular System - Directing Neural Stem Cell Fate in Health and Disease
Current Medicinal Chemistry DNA Methylation and Breast Cancer
Current Genomics subject Index To Volume 2
Current Cancer Drug Targets Advances in Biomarker Research for Pancreatic Cancer
Current Pharmaceutical Design Anti-Cancer Effect of Gingerol in Cancer Prevention and Treatment
Anti-Cancer Agents in Medicinal Chemistry Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site
Anti-Cancer Agents in Medicinal Chemistry Epigenetics in Cystic Fibrosis: Epigenetic Targeting of a Genetic Disease
Current Drug Targets Branched Peptides for the Modulation of Protein-Protein Interactions: More Arms are Better than One?
Current Medicinal Chemistry DNA Methylation: A Possible Target for Current and Future Studies on Cancer?
Epigenetic Diagnosis & Therapy (Discontinued) Proteomic Classification of Breast Cancer
Current Drug Targets